About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Forte Biosciences, Inc. - Common Stock (NQ:FBRX)

43.92 +7.22 (+19.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Forte Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Top movers analysis one hour before the close of the markets on 2026-07-10: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular session. Forte Biosciences (NASDAQ:FBRX) shares moved upwards by 18.39% to $43.45. The market value of... 
Via Benzinga
News headline image
Forte Biosciences' FB102 Hits Key Goal in Vitiligo Study, Shows Durable Improvement ↗
Forte Biosciences (NASDAQ:FBRX) said FB102 showed statistically significant improvement in a small placebo-controlled vitiligo study, with Chief Executive Officer Paul Wagner highlighting continued... 
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX)... 
Via Benzinga
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Forte Biosciences Announces Pricing of $150 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
From Forte Biosciences, Inc.
Via Business Wire
News headline image
Forte Biosciences Tops Q2 Loss Forecasts ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Forte Biosciences, Inc. Announces Results and Provides Update
From Forte Biosciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Forte Biosciences Announces Pricing of $75 Million Public Offering
From Forte Biosciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Forte Biosciences Announces Proposed Public Offering
From Forte Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.